|Description||Asciminib, also known as ABL-001, is a potent and selective allosteric Bcr-Abl inhibitor. Asciminib inhibits Ba/F3 cell growth with an IC50 of 0.25 nM.|
|B0084-007699||10 mg||$248||In stock|
|Solubility||Soluble in DMSO.|
|Storage||Store in a cool and dry place (or refer to the Certificate of Analysis).|
Dasatinib hydrochloride is a potent and dual Abl/ Src inhibitor. It inhibits c-Kit (WT)/c-Kit (D816V).
Flumatinib mesylate, a derivative of imatinib, is a multi-kinase inhibitor for c-Abl, PDGFRβ and c-Kit. It is currently in Phase I and II clinical trials in Chi...
Ponatinib is a novel, potent multi-target inhibitor of Abl, PDGFRα, VEGFR2, FGFR1 and Src with IC50 of 0.37 nM, 1.1 nM, 1.5 nM, 2.2 nM and 5.4 nM, respectively.
GNF-5 is the N-hydroxyethyl carboamide analog of GNF-2, a selective allosteric inhibitor of Bcr-Abl. GNF-5 demonstrates IC50 values of 4.52, 0.38, and 0.93 µM a...
Bafetinib, also known as INNO-406, is an orally bioavailable 2-phenylaminopyrimidine derivative with potential antineoplastic activity. Bafetinib specifically ...
GNF-2 is a Bcr-Abl inhibitor that binds to the myristoyl binding pocket, an allosteric site distant from the active site, stabilizing the inactive form of the k...
ZM306416 is a vascular endothelial growth factor receptor (VEGFR) antagonist.
Nilotinib is a Bcr-Abl inhibitor with IC50 less than 30 nM.
PD-173955 is a src tyrosine kinase inhibitor. PD173955 inhibited Bcr-Abl-dependent cell growth. PD173955 showed cell cycle arrest in G(1). PD173955 has an IC(50...
Dasatinib, also known as BMS-354825, is an orally bioavailable synthetic small molecule-inhibitor of SRC-family protein-tyrosine kinases. Dasatinib binds to and...
GZD824 potently suppressed proliferation of Bcr-Abl-positive K562 and Ku812 human CML cells with IC(50) values of 0.2 and 0.13 nM, respectively. It also display...
Nilotinib monohydrochloride monohydrate
Nilotinib monohydrochloride monohydrate is an orally bioavailable aminopyrimidine-derivative Bcr-Abl tyrosine kinase inhibitor with antineoplastic activity. It ...
DPH is a potent cell permeable c-Abl activator. It binds and alters the conformation of the myristoyl binding site of c-Abl tyrosine kinase. DPH exhibits potent...
PPY A is a potent inhibitor of T315l mutant and wild-type Abl kinases (IC50= 9 and 20 nM, respectively) that inhibits growth of cells transformed with either th...
Bafetinib is a potent and selective dual Bcr-Abl/Lyn inhibitor, but it does not inhibit the phosphorylation of the T315I mutant and is less potent to PDGFR and ...
Rebastinib is an orally bioactive inhibitor of Bcr-Abl that binds to and inhibits Bcr-Abl fusion oncoprotein. Rebastinib changes the conformation of the folded ...
CHMFL-ABL-053 is a potent and orally available inhibitor of BCR-ABL (IC50 = 70nM) without inhibitory activity against c-KIT kinase that is a common target of BC...
Asciminib, also known as ABL-001, is a potent and selective allosteric Bcr-Abl inhibitor. Asciminib inhibits Ba/F3 cell growth with an IC50 of 0.25 nM.
GNF-7 is a type-II T315I inhibitor. GNF-7 inhibits Ack1 and germinal center kinase (GCK). GNF-7 is among the first type-II inhibitors capable of inhibiting T315...
Radotinib, also known as IY-5511, is an orally available, hydrochloride salt form of radotinib, a second-generation tyrosine kinase inhibitor of Bcr-Abl fusion ...